组蛋白去乙酰化酶抑制剂曲古抑菌素A增强溶瘤腺病毒H101对食管鳞状细胞癌的抗肿瘤作用。
Histone deacetylase inhibitor trichostatin A enhances the antitumor effect of the oncolytic adenovirus H101 on esophageal squamous cell carcinoma and .
作者信息
Ma Junfen, Li Nan, Zhao Jimin, Lu Jing, Ma Yanqiu, Zhu Qinghua, Dong Ziming, Liu Kangdong, Ming Liang
机构信息
Department of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China.
Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan 450001, P.R. China.
出版信息
Oncol Lett. 2017 Jun;13(6):4868-4874. doi: 10.3892/ol.2017.6069. Epub 2017 Apr 21.
Abstract
Replication-selective oncolytic virotherapy provides a novel modality to treat cancer by inducing cell death in tumor cells but not in normal cells. However, the utilization of oncolytic viruses as a stand-alone treatment is problematic due to their poor transduction efficiency . H101 was the first oncolytic adenovirus (Ads) to be approved by the Chinese FDA, and exhibits modest antitumor effects when applied as a single agent. The multiple histone deacetylase inhibitor trichostatin A (TSA) has been demonstrated to potently enhance the spread and replication of oncolytic Ads in several infection-resistant types of cancer. The present study aimed to investigate the antitumor effects of H101 in combination with TSA on esophageal squamous cell carcinoma (ESCC) and , and determine the mechanisms underlying these effects. H101 and TSA in combination increased the survival of mice harboring human ESCC cell line-tumor xenografts, as compared with mice treated with these agents individually. Therefore, TSA may enhance the antitumor effects of H101 in ESCC.
摘要
复制选择性溶瘤病毒疗法提供了一种通过诱导肿瘤细胞而非正常细胞死亡来治疗癌症的新方法。然而，由于溶瘤病毒的转导效率低，将其作为单一疗法使用存在问题。H101是首个被中国食品药品监督管理总局批准的溶瘤腺病毒，作为单一药物应用时表现出适度的抗肿瘤效果。多种组蛋白脱乙酰酶抑制剂曲古抑菌素A（TSA）已被证明能有效增强溶瘤腺病毒在几种抗感染类型癌症中的传播和复制。本研究旨在探讨H101与TSA联合应用对食管鳞状细胞癌（ESCC）的抗肿瘤作用，并确定其作用机制。与单独使用这些药物治疗的小鼠相比，H101和TSA联合应用提高了携带人ESCC细胞系肿瘤异种移植瘤小鼠的生存率。因此，TSA可能增强H101对ESCC的抗肿瘤作用。
相似文献
1
Histone deacetylase inhibitor trichostatin A enhances the antitumor effect of the oncolytic adenovirus H101 on esophageal squamous cell carcinoma and .组蛋白去乙酰化酶抑制剂曲古抑菌素A增强溶瘤腺病毒H101对食管鳞状细胞癌的抗肿瘤作用。
Oncol Lett. 2017 Jun;13(6):4868-4874. doi: 10.3892/ol.2017.6069. Epub 2017 Apr 21.
2
Coxsackievirus and adenovirus receptor promotes antitumor activity of oncolytic adenovirus H101 in esophageal cancer.柯萨奇病毒和腺病毒受体促进溶瘤腺病毒 H101 在食管癌中的抗肿瘤活性。
Int J Mol Med. 2012 Dec;30(6):1403-9. doi: 10.3892/ijmm.2012.1133. Epub 2012 Sep 19.
3
A Tumor-Targeted Replicating Oncolytic Adenovirus Ad-TD-nsIL12 as a Promising Therapeutic Agent for Human Esophageal Squamous Cell Carcinoma.一种肿瘤靶向性复制型溶瘤腺病毒Ad-TD-nsIL12作为人食管鳞状细胞癌的一种有前景的治疗剂。
Cells. 2020 Nov 10;9(11):2438. doi: 10.3390/cells9112438.
4
Inhibition of retinoblastoma in vitro and in vivo with conditionally replicating oncolytic adenovirus H101.用条件复制溶瘤腺病毒 H101 在体外和体内抑制视网膜母细胞瘤。
Invest Ophthalmol Vis Sci. 2010 May;51(5):2626-35. doi: 10.1167/iovs.09-3516. Epub 2009 Dec 10.
5
The antitumor effects of oncolytic adenovirus H101 against lung cancer.溶瘤腺病毒H101对肺癌的抗肿瘤作用。
Int J Oncol. 2015 Aug;47(2):555-62. doi: 10.3892/ijo.2015.3045. Epub 2015 Jun 11.
6
An oncolytic adenovirus enhances antiangiogenic and antitumoral effects of a replication-deficient adenovirus encoding endostatin by rescuing its selective replication in nasopharyngeal carcinoma cells.溶瘤腺病毒通过挽救内皮抑素缺失型腺病毒在鼻咽癌细胞中的选择性复制，增强其抗血管生成和抗肿瘤作用。
Biochem Biophys Res Commun. 2013 Dec 13;442(3-4):171-6. doi: 10.1016/j.bbrc.2013.11.047. Epub 2013 Nov 20.
7
Novel three-pronged strategy to enhance cancer cell killing in glioblastoma cell lines: histone deacetylase inhibitor, chemotherapy, and oncolytic adenovirus dl520.
Hum Gene Ther. 2006 Jan;17(1):55-70. doi: 10.1089/hum.2006.17.55.
8
The effects of trichostatin A on the oncolytic ability of herpes simplex virus for oral squamous cell carcinoma cells.曲古抑菌素A对单纯疱疹病毒针对口腔鳞状细胞癌细胞的溶瘤能力的影响。
Cancer Gene Ther. 2009 Mar;16(3):237-45. doi: 10.1038/cgt.2008.81. Epub 2008 Oct 24.
9
Histone deacetylase inhibitor boosts anticancer potential of fusogenic oncolytic vaccinia virus by enhancing cell-cell fusion.组蛋白去乙酰化酶抑制剂通过增强细胞融合增强融合溶瘤痘病毒的抗癌潜力。
Cancer Sci. 2024 Feb;115(2):600-610. doi: 10.1111/cas.16032. Epub 2023 Nov 30.
10
[Effect of CEA gene regulation on the anti-tumor activity of oncolytic adenovirus H101 to esophageal carcinoma].
Zhonghua Zhong Liu Za Zhi. 2011 Nov;33(11):822-6.
引用本文的文献
1
Histone deacetylase inhibitor boosts anticancer potential of fusogenic oncolytic vaccinia virus by enhancing cell-cell fusion.组蛋白去乙酰化酶抑制剂通过增强细胞融合增强融合溶瘤痘病毒的抗癌潜力。
Cancer Sci. 2024 Feb;115(2):600-610. doi: 10.1111/cas.16032. Epub 2023 Nov 30.
2
Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways.通过合理组合溶瘤病毒与靶向关键信号通路的调节剂来改善癌症免疫疗法。
Mol Cancer. 2022 Oct 12;21(1):196. doi: 10.1186/s12943-022-01664-z.
3
Histone modifiers at the crossroads of oncolytic and oncogenic viruses.肿瘤溶瘤病毒和致癌病毒交汇点的组蛋白修饰物。
Mol Ther. 2022 Jun 1;30(6):2153-2162. doi: 10.1016/j.ymthe.2022.02.006. Epub 2022 Feb 8.
4
Efficacy and safety of a third-generation oncolytic herpes virus G47Δ in models of human esophageal carcinoma.第三代溶瘤性疱疹病毒G47Δ在人食管癌模型中的疗效与安全性
Mol Ther Oncolytics. 2021 Oct 30;23:402-411. doi: 10.1016/j.omto.2021.10.012. eCollection 2021 Dec 17.
5
Brd4 Inactivation Increases Adenoviral Delivery of BMP2 for Paracrine Stimulation of Osteogenic Differentiation as a Gene Therapeutic Concept to Enhance Bone Healing.Brd4失活增加腺病毒介导的BMP2递送，用于旁分泌刺激成骨分化，作为一种促进骨愈合的基因治疗概念。
JBMR Plus. 2021 Jun 23;5(10):e10520. doi: 10.1002/jbm4.10520. eCollection 2021 Oct.
6
Oncolytic Viruses in Combination Therapeutic Approaches with Epigenetic Modulators: Past, Present, and Future Perspectives.溶瘤病毒与表观遗传调节剂联合治疗方法：过去、现在和未来展望
Cancers (Basel). 2021 Jun 2;13(11):2761. doi: 10.3390/cancers13112761.
7
YY1 regulated transcription-based stratification of gastric tumors and identification of potential therapeutic candidates.YY1调控基于转录的胃肿瘤分层及潜在治疗候选物的鉴定。
J Cell Commun Signal. 2021 Jun;15(2):251-267. doi: 10.1007/s12079-021-00608-4. Epub 2021 Feb 23.
8
Genome-wide association study of asthma exacerbations despite inhaled corticosteroid use.尽管使用吸入性皮质类固醇，哮喘加重的全基因组关联研究。
Eur Respir J. 2021 May 13;57(5). doi: 10.1183/13993003.03388-2020. Print 2021 May.
9
A Tumor-Targeted Replicating Oncolytic Adenovirus Ad-TD-nsIL12 as a Promising Therapeutic Agent for Human Esophageal Squamous Cell Carcinoma.一种肿瘤靶向性复制型溶瘤腺病毒Ad-TD-nsIL12作为人食管鳞状细胞癌的一种有前景的治疗剂。
Cells. 2020 Nov 10;9(11):2438. doi: 10.3390/cells9112438.
10
Enhancement of adenovirus infection and adenoviral vector-mediated gene delivery by bromodomain inhibitor JQ1.溴结构域抑制剂 JQ1 增强腺病毒感染和腺病毒载体介导的基因传递。
Sci Rep. 2018 Aug 1;8(1):11554. doi: 10.1038/s41598-018-28421-x.
本文引用的文献
1
Elevated p53 expression levels correlate with tumor progression and poor prognosis in patients exhibiting esophageal squamous cell carcinoma.在患有食管鳞状细胞癌的患者中，p53表达水平升高与肿瘤进展及不良预后相关。
Oncol Lett. 2014 Oct;8(4):1441-1446. doi: 10.3892/ol.2014.2343. Epub 2014 Jul 11.
2
Clinical experience with radio-, chemo- and hyperthermotherapy combined trimodality on locally advanced esophageal cancer.放射、化疗及热疗联合三模式治疗局部晚期食管癌的临床经验
Mol Clin Oncol. 2013 Nov;1(6):1009-1012. doi: 10.3892/mco.2013.161. Epub 2013 Jul 26.
3
Neoadjuvant chemoradiotherapy followed by esophagectomy vs. surgery alone in the treatment of resectable esophageal squamous cell carcinoma.新辅助放化疗后行食管切除术与单纯手术治疗可切除食管鳞状细胞癌的比较
Mol Clin Oncol. 2013 Jul;1(4):773-779. doi: 10.3892/mco.2013.128. Epub 2013 May 21.
4
The epigenetic modifier trichostatin A, a histone deacetylase inhibitor, suppresses proliferation and epithelial-mesenchymal transition of lens epithelial cells.组蛋白去乙酰化酶抑制剂曲古抑菌素 A 通过抑制晶状体上皮细胞的增殖和上皮-间充质转化。
Cell Death Dis. 2013 Oct 24;4(10):e884. doi: 10.1038/cddis.2013.416.
5
Antitumor efficacy of a recombinant adenovirus encoding endostatin combined with an E1B55KD-deficient adenovirus in gastric cancer cells.重组内皮抑素基因腺病毒联合 E1B55KD 缺失型腺病毒对胃癌细胞的抗肿瘤作用
J Transl Med. 2013 Oct 14;11:257. doi: 10.1186/1479-5876-11-257.
6
Histone deacetylase inhibitors induce apoptosis in myeloid leukemia by suppressing autophagy.组蛋白去乙酰化酶抑制剂通过抑制自噬诱导髓系白血病细胞凋亡。
Leukemia. 2014 Mar;28(3):577-88. doi: 10.1038/leu.2013.264. Epub 2013 Sep 12.
7
The p53 miRNA interactome and its potential role in the cancer clinic.p53 微小 RNA 相互作用组及其在癌症临床中的潜在作用。
Epigenomics. 2013 Aug;5(4):417-28. doi: 10.2217/epi.13.41.
8
Histone-deacetylase-targeted fluorescent ruthenium(II) polypyridyl complexes as potent anticancer agents.组蛋白去乙酰化酶靶向荧光钌(II)多吡啶配合物作为有效的抗癌药物。
Chemistry. 2013 Jul 29;19(31):10160-9. doi: 10.1002/chem.201300814. Epub 2013 Jul 4.
9
Inhibition of DNA methyltransferases, histone deacetylases and lysine-specific demethylase-1 suppresses the tumorigenicity of the ovarian cancer ascites cell line SKOV3.DNA 甲基转移酶、组蛋白去乙酰化酶和赖氨酸特异性去甲基化酶-1 的抑制作用可抑制卵巢癌腹水细胞系 SKOV3 的致瘤性。
Int J Oncol. 2013 Aug;43(2):495-502. doi: 10.3892/ijo.2013.1960. Epub 2013 May 24.
10
Tumor suppressor p53 plays a key role in induction of both tristetraprolin and let-7 in human cancer cells.抑癌基因 p53 在人类癌细胞中 tristetraprolin 和 let-7 的诱导中发挥关键作用。
Nucleic Acids Res. 2013 Jun;41(11):5614-25. doi: 10.1093/nar/gkt222. Epub 2013 Apr 16.
Zotero 插件